INTRODUCTION
Due to the maturing of the anti-dyslipidemics market, evidenced by the
increasing availability of generic statins, growth in this market has slowed in
recent years. However, increasing prevalence of dyslipidemia and the launch of
novel adjunctive therapies and statin single-pill combinations will drive future
growth
SCOPE OF THE REPORT
- Evaluation of lifecycle management strategies employed to maximize revenue
potential and brand life of agents in all anti-dyslipidemic classes
- Analysis of the impacts of patent expiries from 2003 to 2011 in the US, EU
and Japan on all 1st and 2nd generation statins
- Evaluation of the initial uptake of Crestor vs. Zetia and the longer term
potential of these agents over the forecast period to 2011
- Assessment of the expanding use of combination therapy, following the
launch of novel adjunctive therapies and single-pill combination therapies
REPORT HIGHLIGHTS
In order to minimize the impact of Zocor losing patent protection in the
major markets, Johnson & Johnson MSD Consumer Pharmaceuticals has applied
for OTC status for Zocor in the UK. However, this strategy is unlikely to
maintain Zocor's revenues.
Combination therapy will enable more patients to
achieve target cholesterol goals. As a result, the development of statin
single-pill combinations is an active lifecycle-management strategy for many
statin manufacturers.
Zetia and Crestor represent the newest anti-dyslipidemics
to reach the US and EU, and both agents have been aggressively marketed. The
benefit of using Zetia in combination with statins has led to rapid initial
uptake. However, Crestor has encountered a number of setbacks since launch and
concerns over safety have led to slower initial uptake.
KEY REASONS TO BUY THIS REPORT
- To prioritize sales and marketing efforts to effectively counter
competitive threats
- To select best product lifecycle management strategies to counter generic
competition and expand a drug's commercial potential
- To optimize licensing decisions based on market potential for inline
products and identify optimal R&D development strategies
View Cart
